Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

The International Monetary Fund (IMF) is projecting the global economic growth at 3.3 percent in both 2025 and 2026, below ...

The Dutch economy is projected to grow by a modest 1.3% in 2025, primarily fuelled by consumption. Weak external demand is ...

More than 50,000 people were under evacuation orders or warnings Wednesday as a huge and fast-moving wildfire swept through rugged mountains north of Los Angeles, as parched Southern California ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Keep reading to learn more about this tea, including its potential benefits and side effects ... that the combined effects of bergamot could benefit digestion, more robust studies are needed ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Like most supplements, vitamin B complex can cause side effects, depending on the dose and type of vitamin B. Find a list of ...

Her strategic mindset helps her team engage LSEG's buy- and sell-side clients, providing them with actionable intelligence and getting them access to the biggest voices in business and finance ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...